Skip to main content
. 2016 Apr;4(7):133. doi: 10.21037/atm.2016.03.48

Table 1. Distribution of metabolic comorbidities across the study cohort.

Investigated field N OA
Chi squared (χ2)
Case (+) Control (−) χ2 P value (P)
HTN
   Normal 66 20 (13.2%) 46 (30.5%) 5.934 0.015
   Stage 1 38 16 (10.6%) 22 (14.6%)
   Stage 2 31 20 (13.2%) 11 (7.3%)
   Stage 3 16 14 (9.3%) 2 (1.3%)
Obesity
   BMI (kg/m2)
      18.5≤ BMI <24.0 61 16 (10.6%) 45 (29.8%)
      24.0≤ BMI <28 65 34 (22.5%) 31 (20.5%) 22.242 0.000
      BMI ≥28.0 25 20 (13.2%) 5 (3.3%)
   WC (cm)
      M: WC <85; F: WC <80 56 15 (9.9%) 41 (27.2%)
      M: 85≤ WC <90; F: 80≤ WC <85 31 13 (8.6%) 18 (11.9%) 18.424 0.000
      M: WC ≥90; F: WC ≥85 64 42 (27.8%) 22 (14.6%)
Blood glucose
   Normal 113 53 (35.1%) 60 (39.7%) 0.054 0.817
   Diabetes 38 17 (11.3%) 21 (13.9%)
Lipid metabolism
   Normal 76 25 (16.6%) 51 (33.8%) 11.153 0.001
   Dyslipidaemia 75 45 (29.8%) 30 (19.9%)
Lipid parameters
   TC
      Normal 96 37 (24.5%) 59 (39.1%) 6.475 0.011
      Elevated 55 33 (21.9%) 22 (14.6%)
   TG
      Normal 129 59 (39.1%) 70 (46.4%) 0.137 0.711
      Elevated 22 11 (7.3%) 11 (7.3%)
   HDL-C
      Normal 116 44 (29.1%) 72 (47.7%) 15.163 0.001
      Elevated 3 3 (2.0%) 0 (0%)
      Lower 32 23 (15.2%) 9 (6.0%)
   LDL-C
      Normal 122 52 (34.4%) 70 (46.4%) 3.563 0.059
      Elevated 29 18 (11.9%) 11 (7.3%)
N of metabolic disorders
   0 20 4 (2.6%) 16 (10.6%)
   1 37 8 (5.3%) 29 (19.2%)
   2 49 25 (16.6%) 24 (15.9%) 28.290 0.000
   3 34 25 (16.6%) 9 (6.0%)
   4 11 8 (5.3%) 3 (2.0%)

This table highlights the differences between the distributions of various metabolic disorders between the two groups. N, number; OA, osteoarthritis; HTN, hypertension; BMI, body mass index; WC, waist circumference; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.